Novel noncoding antisense RNA transcribed from human *anti-NOS2A* locus is differentially regulated during neuronal differentiation of embryonic stem cells

SERGEI A. KORNEEV,¹ ELENA I. KORNEEVA,¹ MARYA A. LAGARKOVA,² SERGEI L. KISELEV,² GILES CRITCHLEY,³ and MICHAEL O'SHEA¹

¹Sussex Centre for Neuroscience, School of Life Sciences, University of Sussex, Brighton BN1 9QG, United Kingdom

²Vavilov Institute of General Genetics, Moscow, 119991 Russia

³Hurstwood Park Neurological Centre, Haywards Heath, West Sussex RH16 4EX, United Kingdom

ABSTRACT

Here, we report on the discovery of a locus in the human genome, which evolved by gene duplication followed by an internal DNA inversion. This locus exhibits high sequence similarity to the gene for the inducible isoform of NOS protein (NOS2A) and is transcribed into a noncoding RNA containing a region of significant antisense homology with the *NOS2A* mRNA. We show that this antisense transcript (*anti-NOS2A* RNA) is expressed in different types of brain tumors, including meningiomas and glioblastomas. More importantly, we demonstrate that the expression profiles of the *anti-NOS2A* RNA and the *NOS2A* mRNA exhibit concurrent reciprocal changes in undifferentiated human embryonic stem cells (hESCs) and in hESCs induced to differentiate into neurogenic precursors such as neurospheres. As *NOS2A* has a role in neurogenesis, our results suggest that the *anti-NOS2A* RNA is involved in the regulation of neuronal differentiation of hESCs through the modulation of *NOS2A* gene expression.

Keywords: antisense RNA; DNA inversion; nitric oxide; stem cells; neuronal differentiation

INTRODUCTION

Natural antisense transcripts (NATs) are usually defined as endogenous RNA molecules that are complementary to transcripts of established function. Depending on their origin, NATs can be classified into two major groups: *cis*-encoded (produced from the same loci as their sense counterparts) and *trans*-encoded (transcribed from different loci). Recent studies have shown that NATs are far more abundant in eukaryotic systems than previously thought (Riddihough 2005; Ge et al. 2006; Zhang et al. 2007; Tam et al. 2008; Watanabe et al. 2008), and they appear to be particularly prevalent in the nervous system (for review, see Korneev and O'Shea 2005). In light of the proposed important role of NATs in the regulation of gene expression, attention is now focused on specific examples

of NATs and their contribution to physiological and pathophysiological processes.

Our previous work on a molluscan model system *Lymnaea stagnalis* has shown that a *trans*NAT complementary to the nitric oxide synthase (NOS)-encoding mRNA plays an important role in the regulation of the nitric oxide (NO) signaling pathway in the CNS (Korneev et al. 1999; Korneev et al. 2005). We have also demonstrated that this NAT is transcribed from a *NOS* pseudogene evolved from a duplicated copy of a *NOS* gene by internal DNA inversion (Korneev and O'Shea 2002).

We have now discovered a comparable locus in the human genome, which also evolved by gene duplication followed by an internal DNA inversion reminiscent of our finding in *Lymnaea*. This locus has the highest sequence similarity to the gene encoding the inducible isoform of the NOS protein (*NOS2A*). We named this locus *anti-NOS2A*, and show that it is transcribed into a noncoding NAT containing a region of significant complementarity to *NOS2A* mRNA. This human *anti-NOS2A* RNA is expressed in different types of brain tumors, including meningiomas and glioblastomas. In addition, we demonstrate that the

Reprint requests to: Sergei A. Korneev, Sussex Centre for Neuroscience, School of Life Sciences, University of Sussex, Falmer, Brighton BN1 9QG, UK; e-mail: s.korneev@sussex.ac.uk; fax: 44 (0)1273 678535.

Article and publication are at <http://www.rnajournal.org/cgi/doi/10.1261/rna.1084308>.

expression profiles of the *anti-NOS2A* RNA and the NOS2A mRNA exhibit concurrent reciprocal changes in undifferentiated human embryonic stem cells (hESCs) and in hESCs induced to differentiate into neurogenic precursors. These results suggest that the *anti-NOS2A* RNA plays an important role in the regulation of neuronal differentiation of hESCs through the modulation of NOS2A gene expression.

RESULTS

Human genome contains a locus evolved from a NOS2A gene by partial duplication coupled with internal DNA inversion

From our molluscan studies we know that NOS-related *transNATs* can be transcribed from genomic loci evolved by DNA inversions (Korneev and O'Shea 2002). To reveal similarly organized regions in the human genome we first identified all loci exhibiting significant sequence similarity to NOS-encoding mRNAs. The revealed NOS-homologies have been thoroughly examined using the Lasergene software (DNASTAR). Our aim was to identify those loci, in which relatively long regions exhibiting sense homology with NOS-encoding mRNAs coexist with regions showing antisense homology. Remarkably, such an organization, which is indicative of a DNA inversion, was found to be a characteristic feature of one particular locus. This locus is on chromosome 17 at position q23.3 (contig AC053481.13.1.176235), and has high sequence similarity to the gene encoding the inducible isoform of NOS (NOS2A), located on the same chromosome. Hereafter we will refer to this locus as *anti-NOS2A*, because genomic regions evolved by an internal DNA inversion are a potential source of antisense RNAs (Okano et al. 1988; Tosic et al. 1990; Korneev and O'Shea 2002). No other NOS-homologous loci containing evidence of DNA inversions were found in the human genome. Sequence comparison between the NOS2A gene and the *anti-NOS2A* locus has enabled us to make the following important observations. First, the *anti-NOS2A* locus is about 4 kb, which is significantly shorter than the NOS2A gene (~37 kb). In fact, the homology of the *anti-NOS2A* locus is restricted to exons 15, 16, 17, 18, and 19 and introns 14, 15, 16, 17, 18, and 19 of the NOS2A gene (Fig. 1A). The average sequence identity between the *anti-NOS2A* and corresponding regions of the NOS2A gene is about 80%. Thus, we can conclude that the *anti-NOS2A* locus is the result of a duplication of part of the NOS2A gene. This does not mean, however, that the *anti-NOS2A* locus necessarily retains the same exon/intron organization as the parent gene. In fact, we showed that this locus is intronless (see the next section). Second, computational analysis has confirmed that the organization of the *anti-NOS2A* locus has been affected by an internal DNA inversion. The predicted inverted segment is about 2.5

FIGURE 1. Evolution of *anti-NOS2A* locus. (A) The chain of evolutionary events suggested by our studies and leading to the creation of the *anti-NOS2A* locus in the human genome involved partial duplication (indicated by the linked arrows) of an ancestral NOS2A gene coupled to an internal DNA inversion (hatched box) within the duplicated copy (light gray box). Because of such dramatic disruption of the organization, the *anti-NOS2A* locus cannot produce mature NOS2A mRNA. Instead, it can be transcribed into a NOS2A-related *transNAT*. (B) Organization of orthologous *anti-NOS2A* loci in the human (*Homo sapiens*), orangutan (*Pongo pygmaeus*), chimpanzee (*Pan troglodytes*), and rhesus macaque (*Macaca mulatta*) genomes. Internal DNA inversions are shown by hatched boxes.

kb, and is homologous to introns 16, 17, 18, and 19 and exons 16, 17, 18, and 19 of the original NOS2A gene (Fig. 1A).

Taken together, these observations indicate that the process associated with the evolution of the human *anti-NOS2A* resembles those associated with the evolution of a previously characterized *anti-NOS* locus in a mollusc (Korneev and O'Shea 2002). Both involve gene duplication coupled with an internal DNA inversion (Fig. 1A). Such a remarkable evolutionary similarity suggested to us that the human *anti-NOS2A* locus, if transcribed, could produce functional NOS-related *transNATs*, as does its molluscan counterpart.

We have also investigated whether similarly organized NOS-homologous loci exist in other mammals. Using a bioinformatic approach we analyzed the orangutan (*Pongo pygmaeus*), chimpanzee (*Pan troglodytes*), and rhesus macaque (*Macaca mulatta*) genomes and found that the *anti-NOS2A* locus is conserved in all primates examined

(Fig. 1B). The revealed orthologous loci are located in genomic contigs 7902.2 (chromosome 17), 135.50 (chromosome 17), and 1099214711959 (chromosome 16) in orangutan, chimpanzee, and rhesus macaque, respectively. We have, however, failed to identify similar loci in rodents.

Anti-NOS2A locus is transcribed into a NOS2A-related NAT

In order to investigate transcriptional status of the *anti-NOS2A* locus we have analyzed its nucleotide sequence by using Promoter 2.0 software (Knudsen 1999) designed to identify regulatory elements critical for transcription. A region exhibiting the very high likelihood of the presence of a functional promoter has been found within the inverted region and a potential transcription start site has been identified 436 bp upstream of the inversion breakpoint (Fig. 2A). Notably, the promoter was predicted to drive transcription in the opposite orientation with respect to the *NOS2A* gene, potentially producing an RNA with antisense homology with the *NOS2A* mRNA. No promoter sequences were identified when the *anti-NOS2A* locus was analyzed in the opposite orientation.

To verify the significance of these predictions we employed RT-PCR analysis of RNA extracted from human brain tumors using primers 1 and 2 (Fig. 2A) located downstream of the predicted transcription start site. The results of the experiment shown in Figure 2B fulfill our expectations and demonstrate that the *anti-NOS2A* locus is indeed transcribed in some types of brain malignancies. Moreover, cloning and sequencing of the PCR product shows that it contains a region exhibiting significant homology with the *NOS2A* mRNA. In these RT-PCR experiments we used total RNA and a random primer to produce single-stranded cDNA. This does not select for RNAs in a particular orientation, and so the question of the actual orientation of the detected transcript remains unanswered. In order to address this important issue we set up additional RT-PCR experiments in which cDNA was

FIGURE 2. *Anti-NOS2A* locus is transcribed into noncoding NOS2A-related NAT. (A) Structural organization of human *anti-NOS2A* locus. The inverted part of the locus is shown by the hatched box. Primers used in RT-PCR experiments are numbered. The DNA sequence of the *anti-NOS2A* locus has been analyzed using Promoter 2.0 software (Knudsen 1999). Notably, a region located within the inverted segment has scored 1.082, indicating the very high likelihood of the presence of a functional promoter. The promoter was predicted to drive transcription of the *anti-NOS2A* locus in the opposite orientation with respect to *NOS2A* gene. The putative transcription start site and the direction of transcription are shown by an arrow. A DNA region, transcription of which results in the synthesis of RNA fragment antisense to the *NOS2A* mRNA, is indicated in black. (B) The results of RT-PCR experiments performed on total RNA extracted from human meningioma (lanes 1,2) and glioblastoma (lane 3) using primers 1 and 2 (lanes 1,3) or primers 3 and 4 (lane 2). (C) The results of RT-PCR experiments performed on total RNA from human meningioma using primers 1 and 2. A sequence-specific primer complementary to a putative RNA containing *NOS2A* mRNA-homologous region in antisense orientation was used in the RT reaction. Note that there is no product in the experiments in which reverse transcriptase was omitted from the first strand synthesis reaction (lane 2). (D) The results of RT-PCR experiments performed on total RNA from human meningioma using primers 1 and 2 and either poly(A)⁺ (lanes 1,3) or poly(A)⁻ (lanes 2,4) RNA fractions. Note that there are no products in the experiments in which reverse transcriptase was omitted from the first-strand synthesis reactions (lanes 3,4). (E) Alignment of the antisense region of the *anti-NOS2A* RNA with its complementary counterpart in the *NOS2A* mRNA. In this alignment there is >80% complementarity.

produced using a sequence-specific primer complementary to putative RNA containing the *NOS2A* mRNA-homologous region in antisense orientation. A single band of exactly the expected size has been detected (Fig. 2C). This result confirms

that the *anti-NOS2A* locus is transcribed in human brain tumor into a *transNAT* that contains a region complementary to the conventional *NOS2A* mRNA. Therefore, hereafter we will refer to this transcript as *anti-NOS2A* RNA.

Since total RNA contains both polyadenylated [poly(A)⁺] and nonpolyadenylated [poly(A)[−]] RNA molecules, it was important to know to which class of RNA the *anti-NOS2A* RNA belongs. To answer this question we separated total RNA into poly(A)⁺ and poly(A)[−] RNA fractions. These fractions were then separately subjected to RT-PCR analysis. The results of the experiment presented in Figure 2D show that the PCR product is detected only when poly(A)[−] RNA was used as a template in the RT reaction, indicating that the *anti-NOS2A* RNA belongs to the class of nonpolyadenylated RNAs.

The absence of the poly(A) tail at the 3' end significantly complicates the task of obtaining the full-length version of the *anti-NOS2A* RNA using conventional cDNA cloning techniques such as RACE. To solve this problem we employed another RT-PCR-based approach known as "cDNA walking." Using this strategy we have reconstructed the primary structure of the *anti-NOS2A* RNA from several overlapping cDNA fragments. Sequence analysis of the *anti-NOS2A* RNA has resulted in three important findings. First, the *anti-NOS2A* RNA is a noncoding RNA. Second, there is a perfect uninterrupted match between the *anti-NOS2A* RNA and the corresponding genomic sequence. This indicates that the *anti-NOS2A* locus is intronless. Thus, we can conclude that exon/intron organization of the *anti-NOS2A* locus has been dramatically changed compared to the original *NOS2A* gene. DNA segments which acted as introns in the *NOS2A* gene have lost this function in the novel *anti-NOS2A* locus and become a part of a single "exon." It is noteworthy that similar transition of introns into exons has been reported by us previously when we analyzed the evolution of NOS-related genes in molluscs. Third, we estimated the size of the *anti-NOS2A* RNA to be around 1900 nucleotides (nt), since no product was detected in the RT-PCR experiment in which primers 3 and 4 located just outside of the *anti-NOS2A* locus were used (Fig. 2B). The antisense region of the *anti-NOS2A* RNA is about 100 nt, and exhibits >80% complementarity to *NOS2A* mRNA (Fig. 2E).

***Anti-NOS2A* RNA and *NOS2A* mRNA exhibit concurrent reciprocal changes in their expression during neuronal differentiation of hESCs**

Recent studies indicate that in many types of cancer including certain types of neural malignancies there is a small cell population that exhibits stem cell properties (cancer stem cells) and is responsible for the development and the maintenance of the tumor (Nicolis 2007). This concept recognizes that cancer stem cells share many features with normal stem cells, such as long-term self-

renewal and multipotency. In fact, it was shown that when cultured in the presence of mitogenes, cells from primary brain tumors can give rise to neurospheres. Furthermore, there is evidence that molecular mechanisms regulating the balance between self-replication and terminal differentiation are similar in the two systems (Dreesen and Brivanlou 2007). Based on the above, we hypothesized that the *anti-NOS2A* RNA, which we initially identified in brain tumors, should be also expressed in pluripotent human embryonic stem cells (hESCs). Consequently, we used hESCs as a model system to gain insights into the potential role of the *anti-NOS2A* RNA in the regulation of *NOS2A* gene expression during neuronal differentiation. Specifically, by means of real-time RT-PCR we investigated quantitative changes in the expression levels of the *anti-NOS2A* RNA and *NOS2A* mRNA in undifferentiated hESCs (Fig. 3A) and in hESCs induced to differentiate into neurogenic precursors such as neurospheres (Fig. 3B). Neurospheres are characterized by a premature neuronal phenotype and contain heterogeneous population of glial cells and neurons (Fig. 3C). Two well-established and characterized cell lines, ESM01 and ESM02, were used for this analysis (Lagarkova et al. 2006). Our quantitative experiments have led to the following important observations. First, we found that the expression level of the *anti-NOS2A* RNA in undifferentiated ESM01 is almost 1.5 times higher but in neurospheres

FIGURE 3. The results of real-time RT-PCR performed on hESCs. (A) Colonies of hESM01 on the feeder layer of mouse embryonic fibroblasts. Scale bar represents 200 μ m. (B) Neurospheres derived from hESM01 grown in suspension for 1 wk. Scale bar represents 200 μ m. (C) Immunohistochemical analysis of differentiating neurosphere derived from hESM01. Cells were stained with antibodies against human NSE (green) and GFAP (red). Scale bar represents 200 μ m. (D, E) Circular diagrams illustrating the ratio between relative levels of *NOS2A* mRNA (gray sectors) and *anti-NOS2A* RNA (white sectors) expression in undifferentiated hESM01 (D) and in neurospheres (E) derived from hESM01. The ratios were calculated as $2^{-\Delta C_T(NOS2A)} / 2^{-\Delta C_T(anti-NOS2A)}$.

is ~ 20 times lower than the expression level of *NOS2A* mRNA (Fig. 3D,E). Second, the expression of the *anti-NOS2A* RNA is ~ 7 times higher in the undifferentiated cells than in neurospheres (Fig. 4A). Very similar expression patterns were observed in ESM02 cell line (data not shown). Interestingly, the expression of *NOS2A* mRNA exhibited the opposite dynamics: namely, it was upregulated in neurospheres compared to the undifferentiated cells (Fig. 4B). From these results we can conclude that neuronal differentiation of hESCs is associated with downregulation of the *anti-NOS2A* RNA and upregulation of *NOS2A* mRNA. Thus, there is a clear indication of concurrent reciprocal changes in the expression of the *anti-NOS2A* RNA and *NOS2A* mRNA in undifferentiated hESCs and in neurospheres. This suggests an involvement of the *anti-NOS2A* RNA in neuronal differentiation of hESCs through negative regulation of *NOS2A* gene expression.

DISCUSSION

In our work on evolution of the *NOS* gene family in the pond snail *Lymnaea stagnalis* we found that an ancestral *NOS* gene was duplicated and that one copy retained its original function, whereas an internal DNA inversion occurred in the other (Korneev and O'Shea 2002). We demonstrated that the mutated copy is transcribed into *NOS*-related *transNAT*, which acts as a negative regulator of *NOS* gene expression (Korneev et al. 1999, 2005). Here, we report on the discovery in the human genome of the *anti-NOS2A* locus whose evolution also involved gene duplication followed by an internal DNA inversion. The locus exhibits high sequence identity to the *NOS2A* gene but cannot produce mature *NOS2A* mRNA. Because of this, the *anti-NOS2A* locus can be described formally as an

unprocessed *NOS2A* pseudogene. An additional point emerges from the fact that the orthologous *anti-NOS2A* locus is present in other primates such as orangutan, chimpanzee, and rhesus macaque, but not in nonprimate mammals examined. This suggests that partial duplication of the ancestral *NOS2A* gene coupled to inversion mutation occurred at least 25 million years ago.

Importantly, we found that, exactly as its molluscan counterpart, the human *anti-NOS2A* locus is transcribed into a noncoding *NOS*-related *transNAT*. The remarkable similarity in the process by which the *NAT*-producing loci have evolved in such distantly related organisms suggests strongly that the human *anti-NOS2A* RNA also plays role in the regulation of *NOS* gene expression. An important indication that this is so comes from our quantitative experiments in which we studied the expression of both *anti-NOS2A* RNA and *NOS2A* mRNA in undifferentiated hESCs and hESCs induced to differentiate into neurogenic precursors such as neurospheres. The rationale for this was that in many systems endogenous NO produced by *NOS* enzymes is an important component of intracellular pathways controlling neuronal differentiation. In particular, neurogenesis in the mammalian brain is associated with the upregulation of the *NOS2A* gene expression (Zhu et al. 2003). These findings are in line with the results of our real-time RT-PCR experiments performed on hESCs, which showed a significant increase in the *NOS2A* gene activity during neuronal differentiation of hESCs. The most exciting outcome of our quantitative studies is, however, the revealed concurrent reciprocal changes in the expression of the *anti-NOS2A* RNA and *NOS2A* mRNA in undifferentiated hESCs and in neurospheres. This indicates possible involvement of human *anti-NOS2A* RNA in the regulation of neuronal differentiation of hESCs through the suppression of *NOS2A* gene expression.

FIGURE 4. The expression profiles of the *anti-NOS2A* RNA and the *NOS2A* mRNA exhibit concurrent reciprocal changes in undifferentiated hESCs and in hESCs induced to differentiate into neurospheres. (A, B) The relative levels of *anti-NOS2A* RNA (A) and *NOS2A* mRNA (B) expression normalized to an endogenous control (GAPDH) and relative to a calibrator in undifferentiated hESM01 (dark gray bars) and in neurospheres derived from hESM01 (light gray bars).

Another important aspect of the current paper arises from our findings that the *anti-NOS2A* RNA is expressed in different types of human brain tumor. Experimental work of the past several years has shown that endogenous nitric oxide (NO) produced by NOS2A plays a complex role in tumor biology. Thus, NO production initially induces apoptosis of cells undergoing malignant transformation (Lechner et al. 2005), whereas chronic exposure to NO appears to promote tumor formation (Hussain et al. 2004). These opposing effects probably depend on the local concentration of NOS2A and indicate the existence of molecular machinery delivering fine-tuning of NOS2A gene expression. One potential candidate to fulfill these demands could be a mechanism involving the *anti-NOS2A* RNA we have discovered.

It is of interest to note that the proposed regulatory role of the *anti-NOS2A* RNA is also supported, although indirectly, by experiments conducted on myelin-deficient mice. The genome of mutated mice has undergone exactly the same types of rearrangements we discovered in humans, namely, partial duplication of the gene encoding myelin basic protein (MBP) coupled to a DNA inversion occurring in the duplicated copy (Okano et al. 1988, 1991; Tasic et al. 1990). Moreover, the mutated copy was shown to produce a noncoding *transNAT* that downregulates *MBP* gene expression leading to a phenotype characteristic for myelin-deficient mice.

Finally, the NOS gene family in mammals consists of three distinct genes encoding three major isoforms of NOS protein: neuronal NOS or NOS1, inducible NOS or NOS2A, and endothelial NOS or NOS3 (for review, see Alderton et al. 2001). The NOS proteins catalyze the production of endogenous NO, an important signaling molecule that is also a reactive and toxic gas. Unlike most other chemical neurotransmitters, it cannot be stored and its production must be tightly controlled by a variety of mechanisms operating at different levels (Bredt 2003). Recently, for example, it was reported that a *cisNAT* is involved in post-transcriptional regulation of the expression of the NOS3 gene (Robb et al. 2004; Fish et al. 2007). Until now there was no evidence for the existence of NAT-mediated mechanisms controlling the expression of the two other NOS genes. In the light of the data reported here, however, we can suggest that in addition to the NOS3 gene, the expression of the NOS2A gene can also be regulated by a NAT.

MATERIALS AND METHODS

Computational analysis

The human, orangutan, chimpanzee, macaque rhesus, rat, and mouse genomes available on the NCBI server was analyzed by BlastView algorithm provided by the Ensembl project (Hubbard et al. 2007). The organization of the revealed NOS-homologous loci was studied by using the Lasergene software (DNASTAR).

Promoter 2.0 software (Knudsen 1999) was used to predict transcription start sites within the *anti-NOS2A* locus. On average, the software picks up about 80% of all PolII promoters. Typically, a sequence scoring 0.5–0.8 (marginal prediction) contains about 65% of true promoter sequence. For a sequence scoring 0.8–1.0 (medium likely prediction) this figure is about 80%, and for a region scoring above 1.0 (highly likely prediction) it reaches 95%.

RNA extraction and cDNA synthesis

Total RNA was extracted from human brain tumors and from hESCs by means of Absolutely RNA kit (Stratagene). To remove all traces of genomic DNA the extracted RNA was additionally treated with DNase TURBO according to the manufacturer's protocol (Ambion). Some preparations of the total RNA were separated into poly(A)⁺ and poly(A)[−] fractions by means of Dynabeads oligo-dT₂₅ (Dyna). Purified RNAs were reverse transcribed using iScript cDNA synthesis kit (Bio-Rad).

Verification of the orientation of RNA transcribed from the *anti-NOS2A* locus

In these experiments cDNA synthesis was performed using SuperScript II reverse transcriptase (Invitrogen) and a primer (5'-AGGGTAGGAAGCCCAGAG-3') complementary to putative RNA containing NOS2A mRNA-homologous region in antisense orientation. After the completion of reaction the primer was removed by means of Chroma Spin-100 columns (Clontech).

Conventional PCR

Synthesized cDNAs were subjected to 35 cycles of PCR using HotStar Taq DNA polymerase (QIAGEN) and primers either 5'-TATATGGACATCAGAAGAAACC-3' (primer 1) and 5'-TGGAACTAAGCATATGCTCC-3' (primer 2) or 5'-GAGACATTCAGAGATGGAG-3' (primer 3) and 5'-ACAGGTACGAGAAGTTAGG-3' (primer 4). The identity of PCR products was confirmed by sequencing.

"cDNA walking"

The 287 bp RT-PCR product generated by primers 1 and 2 (see Fig. 2) was sequenced, and a second PCR was conducted using a primer targeting the 287 bp cDNA and a primer targeting the *anti-NOS2A* locus several hundred base pairs downstream of the primer 1. The product of the reaction was sequenced and the whole procedure was then repeated once again. This approach has resulted in the creation of overlapping cDNAs from which the primary structure of the *anti-NOS2A* RNA was reconstructed.

Real-time PCR

cDNAs produced from RNA preparations extracted from undifferentiated hESCs and from neurospheres were amplified and analyzed on the Mx3000 real-time cycler (Stratagene) using QuantiTect SYBR Green PCR kit (QIAGEN) and the following parameters: denaturation, 94°C, 30 sec; annealing, 52°C, 1 min; extension, 72°C, 30 sec. We used primers 5'-TCCAGACCTCAGGTCATC-3' and 5'-AGTATAGGCTGAGCTGCC-3' for the detection of *anti-NOS2A* RNA; primers 5'-GACATCAACAACAA TGTGGAG-3' and 5'-TTCTGCTGCTTGCTGAGG-3' for the

detection of *NOS2A* mRNA; primers 5'-AAGGTGAAGGTCGGA GTC-3' and 5'-GTAAACCATGTAGTTGAGGTC-3' for the detection of *GAPDH* (glyceraldehyde-3-phosphate dehydrogenase) mRNA. The identity of all PCR products was confirmed by sequencing. The amount of target transcript (either *anti-NOS2A* RNA or *NOS2A* mRNA), normalized to an endogenous reference (*GAPDH*) and relative to a calibrator was calculated as $2^{-\Delta\Delta C_T}$ (Pfaffl 2001) where $\Delta\Delta C_T = \Delta C_T - \Delta C_{T(CAL)}$. ΔC_T and $\Delta C_{T(CAL)}$ are the differences in threshold cycles for target and reference measured in the samples and in the calibrator, respectively.

Cultivation and differentiation of hESCs

HESCs were cultured in medium consisted of 80% KnockOut DMEM, 20% FBS, 1 mM glutamine, 1% nonessential amino acids, 50 units/mL penicillin, 50 μ g/mL streptomycin (all from Invitrogen), 0.1 mM β -mercaptoethanol (Sigma), and 4 μ g/mL bFGF (Chemicon) on mitomycin C treated (10 μ g/mL, Sigma) mouse embryonic fibroblasts (MEF) using tissue culture dishes precoated with 0.1% gelatin (Merck). MEFs were prepared from day 12.5 p.c. fetuses of F1 (C57BL/6J $\times$ CBA/Ca) mice. hESC colonies were replated every 5–6 d by exposure to type IV collagenase (200 U/mL, Invitrogen) followed by mechanical dissociation. Cells between passages 20 and 23 were used for the real-time RT-PCR analysis.

Differentiation of hESCs into neurospheres was performed as described (Gerrard et al. 2005; Itsykson et al. 2005) with some modifications. To induce neuronal differentiation dishes with undifferentiated hESCs grown for 7 d were treated with collagenase IV for 10 min, washed twice with growth medium, and collected. Colonies were transferred to new 35 mm Petri dishes precoated with poly L-lysine and laminin (Sigma) and cultivated in DMEM/F12 (Hyclone) containing N2 and B27 supplements (Invitrogen), 50 ng/mL recombinant human noggin (Chemicon), and 20 ng/mL bFGF (Chemicon). Medium was changed every 2 d. After 2 wk of cultivation rosette-like structures were collected and cultivated in suspension in 12-well plates precoated with 1.5% Agarose (Bio-Rad). After 5 d, cell clumps displayed typical neurosphere morphology. Neurospheres were propagated for 2 wk in DMEM/F12 (Hyclone) containing N2 and B27 supplements (Invitrogen), 20 ng/mL bFGF (Chemicon), and 10 ng/mL EGF (Sigma).

Immunohistochemistry

Cultured cells were fixed in 100% ice-cold methanol for 5 min, washed for 1 h in blocking buffer (PBS, 0.1% Tween-20, 5% FBS, 2% goat serum), and incubated for 1 h at room temperature with primary mouse antihuman neuron-specific enolase (NSE) (1:50; Chemicon) and rabbit antihuman glial fibrillary acidic protein (GFAP) (1:1000; Chemicon) antibodies in PBS, 0.1% Tween 20. Following three washes with PBS, 0.1% Tween 20, cells were incubated with secondary antibodies: Alexa Fluor 488-conjugated goat antimouse IgG and Alexa Fluor 546-conjugated goat anti-rabbit IgG (diluted 1:800; Molecular Probes).

ACKNOWLEDGMENTS

This work was supported by a Wellcome Trust grant. Funding to pay the Open Access publication charges for this article was provided by Wellcome Trust.

Received March 18, 2008; accepted June 19, 2008.

REFERENCES

- Alderton, W.K., Cooper, C.E., and Knowles, R.G. 2001. Nitric oxide synthase: Structure, function and inhibition. *Biochem. J.* **357**: 593–615.
- Bredt, D.S. 2003. Nitric oxide signaling specificity—The heart of the problem. *J. Cell Sci.* **116**: 9–15.
- Dreesen, O. and Brivanlou, A.H. 2007. Signaling pathways in cancer and embryonic stem cells. *Stem Cell Rev.* **3**: 7–17.
- Fish, J.E., Matouk, C.C., Yeboah, E., Bevan, S.C., Khan, M., Patil, K., Ohh, M., and Marsden, P.A. 2007. Hypoxia-inducible expression of a natural *cis*-antisense transcript inhibits endothelial nitric-oxide synthase. *J. Biol. Chem.* **282**: 15652–15666.
- Ge, X., Wu, Q., Jung, Y.-C., Chen, J., and Wang, S.M. 2006. A large quantity of novel human antisense transcripts detected by LongSAGE. *Bioinformatics* **22**: 2475–2479.
- Gerrard, L., Rodgers, L., and Cui, W. 2005. Differentiation of human embryonic stem cells to neural lineages in adherent culture by blocking bone morphogenetic protein signaling. *Stem Cells* **23**: 1234–1241.
- Hubbard, T.J., Aken, B.L., Beal, K., Ballester, B., Caccamo, M., Chen, Y., Clarke, L., Coates, G., Cunningham, F., Cutts, T., et al. 2007. Ensembl 2007. *Nucleic Acids Res.* **35**: D610–D617.
- Hussain, S.P., Trivers, G.E., Hofseth, L.J., He, P., Shaikh, I., Mechanic, L.E., Doja, S., Jiang, W., Subleski, J., Shorts, L., et al. 2004. Nitric oxide, a mediator of inflammation, suppresses tumorigenesis. *Cancer Res.* **64**: 6849–6853.
- Itsykson, P., Ilouz, N., Turetsky, T., Goldstein, R.S., Pera, M.F., Fishbein, I., Segal, M., and Reubinoff, B.E. 2005. Derivation of neural precursors from human embryonic stem cells in the presence of noggin. *Mol. Cell. Neurosci.* **30**: 24–36.
- Knudsen, S. 1999. Promoter 2.0: for the recognition of PolII promoter sequences. *Bioinformatics* **15**: 356–361.
- Korneev, S.A. and O'Shea, M. 2002. Evolution of nitric oxide synthase regulatory genes by DNA Inversion. *Mol. Biol. Evol.* **19**: 1228–1233.
- Korneev, S.A. and O'Shea, M. 2005. Natural antisense RNAs in the nervous system. *Rev. Neurosci.* **16**: 213–222.
- Korneev, S.A., Park, J.-H., and O'Shea, M. 1999. Neuronal expression of neural nitric oxide synthase (nNOS) protein is suppressed by an antisense RNA transcribed from a NOS pseudogene. *J. Neurosci.* **19**: 7711–7720.
- Korneev, S.A., Straub, V., Kemenes, I., Korneeva, E.I., Ott, S.R., Benjamin, P.R., and O'Shea, M. 2005. Timed and targeted differential regulation of NOS and antiNOS genes by reward conditioning leading to long-term memory formation. *J. Neurosci.* **25**: 1188–1192.
- Lagarkova, M.A., Volchkov, P.Y., Lyakisheva, A.V., Philonenko, E.S., and Kiselev, S.L. 2006. Diverse epigenetic profile of novel human embryonic stem cell lines. *Cell Cycle* **5**: 416–420.
- Lechner, M., Lirk, P., and Rieder, J. 2005. Inducible nitric oxide synthase (iNOS) in tumor biology: The two sides of the same coin. *Semin. Cancer Biol.* **15**: 277–289.
- Nicolis, S.K. 2007. Cancer stem cells and “stemness” genes in neuro-oncology. *Neurobiol. Dis.* **25**: 217–229.
- Okano, H., Ikenaka, K., and Mikoshiba, K. 1988. Recombination within the upstream gene of duplicated myelin basic protein genes of myelin deficient *shim1d* mouse results in the production of antisense RNA. *EMBO J.* **7**: 3407–3412.
- Okano, H., Aruga, J., Nakagawa, T., Shiota, C., and Mikoshiba, K. 1991. Myelin basic protein gene and the function of antisense RNA in its repression in myelin-deficient mutant mouse. *J. Neurochem.* **56**: 560–567.
- Pfaffl, M.W. 2001. A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res.* **29**: e45. doi: 10.1093/nar/29.9.e45.
- Riddihough, G. 2005. In the forest of RNA dark matter. *Science* **309**: 1507.
- Robb, G.B., Carson, A.R., Tai, S.C., Fish, J.E., Singh, S., Yamada, T., Scherer, S.W., Nakabayashi, K., and Marsden, P.A. 2004.

- Post-transcriptional regulation of endothelial nitric-oxide synthase by an overlapping antisense mRNA transcript. *J. Biol. Chem.* **279**: 37982–37996.
- Tam, O.H., Aravin, A.A., Stein, P., Girard, A., Murchison, E.P., Cheloufi, S., Hodges, E., Anger, M., Sachidanandam, R., Schultz, R.M., et al. 2008. Pseudogene-derived small interfering RNAs regulate gene expression in mouse oocytes. *Nature* **453**: 534–538.
- Tosic, M., Roach, A., de Rivaz, J.C., Dolivo, M., and Matthieu, J.M. 1990. Post-transcriptional events are responsible for low expression of myelin basic protein in myelin deficient mice: Role of natural antisense RNA. *EMBO J.* **9**: 401–406.
- Watanabe, T., Totoki, Y., Toyoda, A., Kaneda, M., Kuramochi-Miyagawa, S., Obata, Y., Chiba, H., Kohara, Y., Kono, T., Nakano, T., et al. 2008. Endogenous siRNAs from naturally formed dsRNAs regulate transcripts in mouse oocytes. *Nature* **453**: 539–543.
- Zhang, Y., Li, J., Kong, L., Gao, G., Liu, Q.-R., and Wei, L. 2007. NATsDB: Natural antisense transcripts database. *Nucleic Acids Res.* **35**: D156–D161.
- Zhu, D.Y., Liu, S.H., Sun, H.S., and Lu, Y.M. 2003. Expression of inducible nitric oxide synthase after focal cerebral ischemia stimulates neurogenesis in the adult rodent dentate gyrus. *J. Neurosci.* **23**: 223–229.

RNA

A PUBLICATION OF THE RNA SOCIETY

Novel noncoding antisense RNA transcribed from human *anti-NOS2A* locus is differentially regulated during neuronal differentiation of embryonic stem cells

Sergei A. Korneev, Elena I. Korneeva, Marya A. Lagarkova, et al.

RNA 2008 14: 2030-2037

References This article cites 27 articles, 8 of which can be accessed free at:
<http://rnajournal.cshlp.org/content/14/10/2030.full.html#ref-list-1>

Open Access Freely available online through the RNA Open Access option.

License Freely available online through the open access option.

Email Alerting Service Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

To subscribe to RNA go to:
<http://rnajournal.cshlp.org/subscriptions>